tirzepatide from manufacturer FDA Says Compounded Must Exit the Market FDA Clarifies Compounding Rules as

Among the 5,442 GI adverse events reported to the FDA, eructation had a reporting odds ratio of 42.03

Trial SUSTAIN-6 (Marso et al., NEJM 2016) Design Phase 3 / 104 weeks Population 3,297 adults with T2D at high CV risk Key result 26% MACE reduction (HR 0.74

Understanding how it compares to alternatives helps researchers make informed decisions about product sourcing

A separate company, calling itself BioBlue Cosmetics but also operating as BioBlue Fitness, is selling so-called skinny jabs under the guise of exercise programmes

The pronounced difference in molecular weight (~5196 vs

Intranasal midazolam premedication for digital image-assisted Fundus examination in preterm neonates